{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["74"],"submitter":["Huang JF"],"pubmed_abstract":["Background
Masked hypertension is associated with target organ damage (TOD) and adverse health outcomes, but whether antihypertensive treatment improves TOD in patients with masked hypertension is unproven.Methods
In this multicentre, randomised, double-blind, placebo-controlled trial at 15 Chinese hospitals, untreated outpatients aged 30-70 years with an office blood pressure (BP) of <140/<90 mm Hg and 24-h, daytime or nighttime ambulatory BP of ≥130/≥80, ≥135/≥85, or ≥120/≥70 mm Hg were enrolled. Patients had ≥1 sign of TOD: electrocardiographic left ventricular hypertrophy (LVH), brachial-ankle pulse wave velocity (baPWV) ≥1400 cm/s, or urinary albumin-to-creatinine ratio (ACR) ≥3.5 mg/mmol in women and ≥2.5 mg/mmol in men. Exclusion criteria included secondary hypertens"],"journal":["EClinicalMedicine"],"pagination":["102736"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11293515"],"repository":["biostudies-literature"],"pubmed_title":["Efficacy of antihypertensive treatment for target organ protection in patients with masked hypertension (ANTI-MASK): a multicentre, double-blind, placebo-controlled trial."],"pmcid":["PMC11293515"],"pubmed_authors":["An DW","Hu Z","Liao YY","Zhu MY","Lu Y","Chang GL","Zhang M","Yu J","Dai QY","Li XD","Li MX","Chen XP","Dou Y","Huang JY","Liu HX","Guo H","Zhang YQ","Yu W","Liu LX","Zhu LL","Xu XL","Chen X","Wang JG","Ma RX","Zhang DY","Bu PL","Xu JT","Zhang HJ","Meng QT","Zhu YF","Zhang JS","Mu JJ","Feng YQ","Zheng QD","ANTI-MASK Investigators","Yu YL","Liang XY","Wang WJ","Li Y","Jiang YN","Liu CY","Staessen JA","Zhang Y","Liu C","Wang YY","Huang JF","Zhang XN","Zhang ZP"],"additional_accession":[]},"is_claimable":false,"name":"Efficacy of antihypertensive treatment for target organ protection in patients with masked hypertension (ANTI-MASK): a multicentre, double-blind, placebo-controlled trial.","description":"Background
Masked hypertension is associated with target organ damage (TOD) and adverse health outcomes, but whether antihypertensive treatment improves TOD in patients with masked hypertension is unproven.Methods
In this multicentre, randomised, double-blind, placebo-controlled trial at 15 Chinese hospitals, untreated outpatients aged 30-70 years with an office blood pressure (BP) of <140/<90 mm Hg and 24-h, daytime or nighttime ambulatory BP of ≥130/≥80, ≥135/≥85, or ≥120/≥70 mm Hg were enrolled. Patients had ≥1 sign of TOD: electrocardiographic left ventricular hypertrophy (LVH), brachial-ankle pulse wave velocity (baPWV) ≥1400 cm/s, or urinary albumin-to-creatinine ratio (ACR) ≥3.5 mg/mmol in women and ≥2.5 mg/mmol in men. Exclusion criteria included secondary hypertens","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Aug","modification":"2026-04-17T13:05:27.142Z","creation":"2025-04-19T20:48:24.204Z"},"accession":"S-EPMC11293515","cross_references":{"pubmed":["39091669"],"doi":["10.1016/j.eclinm.2024.102736"]}}